SCHEMBL29398697

SCHEMBL29398697

COc1ncccc1-c1cnn2ccc(N3CCN(C(=O)OC4(C)COC4)CC3)nc12

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AAK1 Q2M2I8 1/20 0.72
▸ JAK2 O60674 2/20 0.39
▸ JAK3 P52333 1/20 0.39
▸ PTK2 Q05397 1/20 0.39
▸ GAA P10253 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ NTRK1 P04629 4/20 0.37
▸ SMO Q99835 1/20 0.37
▸ SMPD3 Q9NY59 5/20 0.37
▸ SCN9A Q15858 1/20 0.36
▸ HRH4 Q9H3N8 1/20 0.35
▸ PIM1 P11309 2/20 0.35
▸ PIM2 Q9P1W9 2/20 0.35
▸ TSHR P16473 2/20 0.34
▸ HSD17B10 Q99714 2/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ CYP2D6 P10635 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ USP2 O75604 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17099735 1.00 AAK1 (0.72) AAK1JAK2JAK3PTK2GAA
SCHEMBL31441763 0.91 AAK1 (0.66) AAK1GAANPSR1NTRK1SMO
SCHEMBL31441725 0.91 AAK1 (0.66) AAK1GAANPSR1NTRK1SMO
SCHEMBL31441491 0.90 AAK1 (0.59) AAK1
SCHEMBL30172448 0.90 AAK1 (0.58) AAK1JAK2JAK3PTK2GAA
SCHEMBL30172443 0.90 AAK1 (0.58) AAK1JAK2JAK3PTK2GAA
SCHEMBL31441524 0.90 AAK1 (0.58) AAK1NTRK1
SCHEMBL31441533 0.89 AAK1 (0.56) AAK1GAANPSR1NTRK1SMO
SCHEMBL31441484 0.89 AAK1 (0.56) AAK1GAANPSR1NTRK1SMO
SCHEMBL31441686 0.89 AAK1 (0.57) AAK1NTRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3719021-B1 INHIBITORS OF ADAPTER ASSOCIATED KINASE 1, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE LEXICON PHARMACEUTICALS INC (US) 2022-03-09 — — EP claimed
US-20250270222-A1 AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF SATELLOS BIOSCIENCE INC. (CA) 2025-08-28 — — US disclosed
US-20250122207-A1 AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF SATELLOS BIOSCIENCE INC. (CA) 2025-04-17 — — US disclosed
EP-4532692-A1 MODULATION OF SATELLITE CELL POLARITY AND ASYMMETRIC CELL DIVISION Ottawa Hospital Research Institute (CA) 2025-04-09 — — EP disclosed
WO-2025054448-A1 AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF SATELLOS BIOSCIENCE INC. (CA) 2025-03-13 — — WO disclosed
WO-2023230523-A1 MODULATION OF SATELLITE CELL POLARITY AND ASYMMETRIC CELL DIVISION OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) 2023-11-30 — — WO disclosed
CN-115427045-A 4- (3- (pyridin-3-yl) pyrazolo [1,5-a ] pyrimidin-5-yl) piperazine for the treatment of COV-229E or COV-OC43 coronavirus infection 莱西肯医药有限公司 2022-12-02 — — CN disclosed
EP-3719021-B1 INHIBITORS OF ADAPTER ASSOCIATED KINASE 1, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE LEXICON PHARMACEUTICALS INC (US) 2022-03-09 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250122207-A1 AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF AAK1, CAMKK1, AP2A1 AAK1 1/4885JAK2 695/4885JAK3 1275/4885
US-20250270222-A1 AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF AAK1, AP2A1, CSNK1A1 AAK1 1/4885JAK2 1352/4885JAK3 1720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback